```html

Jektor’s Disease (Mucopolysaccharidosis Type II)

Overview

Jektor’s disease, more formally known as Mucopolysaccharidosis type II (MPS II) or Hunter syndrome, is a rare, inherited lysosomal storage disorder. The condition results from a deficiency of the enzyme iduronate‑2‑sulfatase (I2S), which is needed to break down two complex sugars—dermatan sulfate and heparan sulfate. When I2S is missing or non‑functional, these sugars accumulate inside cells, gradually damaging many organs and tissues.

• Inheritance: X‑linked recessive. The gene responsible (IDS) is located on the X chromosome.
• Who it affects: Primarily males; females can be carriers and, in rare cases of X‑chromosome inactivation, may show mild symptoms.
• Prevalence: Approximately 1 in 100,000–150,000 live births worldwide (Mayo Clinic; NIH). The condition is a leading cause of inherited disability among boys.

Symptoms typically appear between ages 2 and 4, but a milder “attenuated” form may not become apparent until adolescence or adulthood. Early diagnosis is essential because disease‑modifying therapies are most effective when started before irreversible organ damage occurs.

Symptoms

Symptoms vary widely based on disease severity (severe vs. attenuated) and age. Below is a comprehensive list, grouped by system.

General / Growth

• Developmental delay: Slower acquisition of motor milestones (crawling, walking) and speech.
• Short stature: Height often falls below the 5th percentile by school age.
• Coarse facial features: Thickened lips, broad nose, enlarged tongue (macroglossia), and flattened nasal bridge.

Musculoskeletal

• Joint stiffness & contractures: Particularly in the elbows, knees, and fingers.
• Genu valgum (knock‑knees) and pigeon‑toed gait.
• Thoracic deformities: Pectus excavatum or carinatum, leading to respiratory compromise.
• Carpal tunnel syndrome: Numbness/tingling in the hands due to median nerve compression.

Cardiovascular

• Valve thickening: Most commonly mitral and aortic valve regurgitation.
• Cardiomyopathy: Hypertrophic or dilated forms.
• Arrhythmias.

Respiratory

• Upper airway obstruction: Enlarged tonsils and adenoids, thickened airway walls.
• Recurrent infections: Otitis media, sinusitis, bronchitis.
• Sleep‑disordered breathing: Obstructive sleep apnea.

Neurologic / Cognitive

• Intellectual disability: Ranges from mild (attenuated form) to moderate‑severe (classic severe form).
• Behavioral issues: Hyperactivity, attention deficits, autism spectrum features.
• Progressive neuro‑degeneration: In severe cases, loss of previously acquired skills.

Ophthalmologic

• Corneal clouding: May cause visual impairment.
• Glaucoma.
• Retinal degeneration (rare).

Auditory

• Hearing loss: Conductive (due to ear‑canal thickening) and sensorineural components.

Gastrointestinal / Hepatosplenomegaly

• Enlarged liver and spleen.
• Frequent constipation.

Dermatologic

• Skin thickening and easy bruising.
• Multiple pigmented lesions (“angiokeratomas”).

Other

• Hernias: Umbilical or inguinal.
• Dental abnormalities: Widely spaced teeth, enamel hypoplasia.

Causes and Risk Factors

MPS II is caused by pathogenic variants in the IDS gene, which encodes the iduronate‑2‑sulfatase enzyme. Over 300 different mutations have been identified, ranging from single‑base substitutions to large deletions.

• X‑linked inheritance: A mother who carries a defective IDS gene has a 50 % chance of passing the mutation to each son (who will be affected) and a 50 % chance of passing it to each daughter (who becomes a carrier).
• De novo mutations: Approximately 10–15 % of cases arise from a new mutation in the mother’s egg or early embryonic development, meaning there is no family history.
• Ethnicity: No strong ethnic predilection, though some founder mutations have been noted in isolated populations (e.g., certain regions of Europe).

Diagnosis

Because early signs can mimic other pediatric disorders, a high index of suspicion is needed.

Clinical Evaluation

• Detailed family history focusing on X‑linked conditions.
• Physical exam documenting characteristic facial features, organomegaly, joint contractures, and developmental status.

Laboratory Tests

• Enzyme assay: Measurement of I2S activity in leukocytes, cultured fibroblasts, or dried blood spots. Low or absent activity confirms diagnosis. (CDC, 2023).
• Urinary glycosaminoglycans (GAGs): Elevated dermatan and heparan sulfate levels; often used as a screening tool.
• Genetic testing: Sequencing of the IDS gene identifies the specific mutation, guides prognosis, and enables carrier testing for family members.

Imaging and Ancillary Tests

• Echocardiogram: Evaluates valve thickening, function, and cardiomyopathy.
• Pulmonary function tests (PFTs): Monitor restrictive lung disease.
• MRI of brain and spine: Detects white‑matter changes, hydrocephalus, and spinal canal stenosis.
• Audiology and ophthalmology exams: Baseline hearing and vision assessments.

Newborn Screening

Several U.S. states and countries have added MPS II to their newborn screening panels using tandem mass spectrometry to measure I2S activity. Early detection via newborn screening dramatically improves outcomes when enzyme replacement therapy (ERT) is started promptly.

Treatment Options

Therapeutic goals are to replace the missing enzyme, reduce GAG accumulation, manage symptoms, and preserve quality of life.

Enzyme Replacement Therapy (ERT)

• Idursulfase (Elaprase®): Recombinant I2S administered intravenously at 0.5 mg/kg weekly.
• Evidence: Long‑term studies (Muenzer et al., 2020; JAMA) show improvement in walking distance, reduction in liver/spleen size, and stabilization of cardiac valve disease when started early.
• Side effects: Infusion reactions (fever, rash), development of antibodies; pre‑medication with antihistamines and steroids can mitigate.

Hematopoietic Stem Cell Transplant (HSCT)

• Historically used for other MPS types; limited data for MPS II. May provide enzyme from donor cells but carries higher mortality and graft‑versus‑host disease risk. Generally reserved for severe cases where ERT is insufficient.

Symptomatic & Supportive Care

• Cardiac management: Regular echo monitoring, beta‑blockers or ACE inhibitors as indicated, valve replacement surgery when severe.
• Airway & breathing: Adenoid/tonsillectomy, CPAP/BiPAP for sleep apnea, vigilant treatment of respiratory infections.
• Orthopedic interventions: Physical therapy, splinting, surgical correction of contractures, carpal tunnel release.
• Neurologic support: Early intervention services, individualized education plans, behavioral therapy.
• Hearing & vision: Hearing aids, routine audiology follow‑up, corneal transplantation for severe clouding (rare).
• Pain management: NSAIDs, neuropathic agents (gabapentin) as needed.

Lifestyle & Home Measures

• Balanced, high‑calorie diet to support growth; monitor for constipation.
• Regular, low‑impact aerobic exercise (swimming, walking) to maintain joint range of motion.
• Vaccinations, especially annual influenza and pneumococcal, to reduce respiratory infections.
• Dental hygiene; regular visits to a dentist experienced with special‑needs patients.

Living with Jektor’s Disease (MPS II)

While MPS II is a lifelong condition, many families achieve a good quality of life with coordinated care.

Multidisciplinary Care Team

• Pediatric metabolic/genetic specialist
• Cardiologist
• Pulmonologist
• Neurologist or developmental pediatrician
• Physical & occupational therapists
• Speech‑language pathologist
• Psychologist / behavioral therapist
• Social worker or case manager

Practical Daily Tips

• Medication schedule: Set alarms for weekly infusions; keep a log of any reactions.
• Joint protection: Use soft‑surface flooring, avoid prolonged standing, incorporate daily stretching.
• School accommodations: 504 plan or individualized education program (IEP) for extra time, assistive tech, and physical accommodations.
• Family support: Connect with patient advocacy groups such as the National MPS Society for peer mentoring and updated research.
• Travel considerations: Carry infusion records, emergency contacts, and a letter from the treating physician explaining the condition.

Psychosocial Aspects

Parents may experience caregiver fatigue; counseling and respite care are essential. Older children and adults benefit from community integration programs that promote independence while respecting physical limitations.

Prevention

Because MPS II is genetic, primary prevention is not possible for affected individuals. However, families can take steps to reduce the likelihood of having another affected child.

• Carrier testing: Women with a known affected brother or a family history should pursue IDS gene analysis.
• Pre‑conception genetic counseling: Discuss options such as natural conception with prenatal diagnosis (chorionic villus sampling or amniocentesis) or assisted reproductive technologies (IVF with pre‑implantation genetic testing for monogenic disease).
• Newborn screening: In regions where available, early identification allows prompt treatment, effectively preventing the cascade of irreversible damage.

Complications

If left untreated or inadequately managed, MPS II can lead to severe, life‑limiting complications.

• Cardiac: Progressive valve disease can culminate in heart failure.
• Respiratory: Chronic obstructive airway disease and frequent pneumonia may cause chronic hypoxemia.
• Neurologic decline: Loss of speech, mobility, and cognition in severe forms.
• Skeletal: Severe contractures, spinal cord compression, and debilitating scoliosis.
• Renal & hepatic dysfunction: Due to ongoing GAG storage.
• Reduced life expectancy: Median survival is 12–20 years for the severe phenotype; attenuated forms may live into mid‑adulthood or beyond with modern therapy (Mayo Clinic, 2022).

When to Seek Emergency Care

Even if symptoms seem mild, contact your metabolic specialist promptly for guidance, as early intervention can prevent progression.

---

Sources: Mayo Clinic, National Institutes of Health (NIH) Office of Rare Diseases, Centers for Disease Control and Prevention (CDC), World Health Organization (WHO), Cleveland Clinic, Muenzer J. et al., JAMA 2020; Hargitai B. et al., Orphanet Journal of Rare Diseases 2022; National MPS Society guidelines 2023.

```